Trial Profile
A Multicenter, Open Label, Escalating Dose Study to Assess the Tolerability and the Safety and to Explore the Efficacy and the Pharmacokinetics of ND0801 in Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Dec 2019
Price :
$35
*
At a glance
- Drugs Nictoine/opipramol (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors NeuroDerm
- 04 Dec 2019 Status changed from recruiting to completed.
- 26 Dec 2017 Planned End Date changed from 1 Dec 2013 to 1 Dec 2017.
- 05 Nov 2012 Planned end date changed from 1 Apr 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.